Protagonist Therapeutics, Inc (PTGX): Cash & Equivalents
$128.39M
As of 2025-12-31
$420.08M
As of 2026-06-30
+0.7%
3-year compound annual growth
+1.8%
5-year compound annual growth
+41.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $128.39M | +32.0% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $97.25M | -47.9% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $186.73M | +48.5% | 2026-02-25, Balance as of period end |
| 2022-12-31 | $125.74M | +1.7% | 2025-02-21, Balance as of period end |
| 2021-12-31 | $123.67M | +5.4% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $117.36M | +255.6% | 2023-03-15, Balance as of period end |
| 2019-12-31 | $33.01M | -59.9% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $82.23M | -22.4% | 2021-03-10, Balance as of period end |
| 2017-12-31 | $106.03M | +402.9% | 2020-03-10, Balance as of period end |
| 2016-12-31 | $21.08M | +420.0% | 2019-03-12, Balance as of period end |
| 2015-12-31 | $4.05M | -56.5% | 2018-03-07, Balance as of period end |
| 2014-12-31 | $9.32M | n/a | 2017-03-07, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $128.39M | +32.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $120.72M | -49.3% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $11.44M | -36.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $137.53M | +148.7% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $37.73M | -18.1% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $602.07M | +99.3% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $34.33M | -48.5% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $6.39M | +8.2% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $737.06M | +88.0% |
Compare PTGX, SEPN, CPIX, XLO side by side · Screen every company in Pharmaceutical Preparations ↗